Neues aus der Kinder-Rheumatologie

Hartmut Michels; Renate Häfner

doi:10.1055/s-0037-1618501

Arthritis und Rheuma, Table of Contents

Arthritis und Rheuma 2005; 25(03): 141-148
DOI: 10.1055/s-0037-1618501

Innovationen auf dem Prüfstand

Schattauer GmbH

Neues aus der Kinder-Rheumatologie

Recent developments in pediatric rheumatology

Hartmut Michels

¹Deutsches Zentrum für Kinder- und Jugendrheumatologie Garmisch-Partenkirchen (Ärztlicher Direktor: Dr. H. Michels)

,

Renate Häfner

¹Deutsches Zentrum für Kinder- und Jugendrheumatologie Garmisch-Partenkirchen (Ärztlicher Direktor: Dr. H. Michels)

› Author Affiliations

Abstract

Zusammenfassung

Bemerkenswerte Fortschritte in der Kinder- und Jugendrheumatologie haben während der letzten 15 Jahre zu einer Verbesserung der Langzeitprognose der juvenilen idiopathischen Arthritis (JIA) geführt. Bei den chronischen Arthritiden setzt sich zunehmend die JIA-Klassifikation durch. Für Studien wurden Verbesserungskriterien entwickelt, die eine Entscheidung darüber ermöglichen, ob im Verlauf eine Verbesserung erzielt wurde oder nicht. Diagnostisch hat die Identifizierung der genetischen Defekte bei periodischen Fiebersyndromen wie Muckle-Wells-Syndrom eine klare Abgrenzung zur systemischen JIA (sJIA) ermöglicht. Basistherapeutisch stellt Methotrexat (MTX) bei der JIA nach wie vor den „Goldstandard“ dar. Im Rahmen einer multizentrischen, internationalen Studie konnte jedoch gezeigt werden, dass bei unzureichender Effektivität eine Do-siserhöhung über 15 mg MTX/m² KOF/Woche keinen zusätzlichen Gewinn bringt. In solchen Fällen kann Etanercept erwogen werden, das allerdings bei sJIA häufig unwirksam ist.

Von den bildgebenden Verfahren hat die Sonographie in der Kinderrheumatologie wegen der fehlenden Strahlenbelastung und beliebigen Wiederholbarkeit eine Sonderstel-lung inne. Das Röntgenbild hat in der Verlaufsbeobachtung der JIA nach wie vor Bedeutung und ist wie auch die Kernspintomographie darüber hinaus für die Differenzialdiagnostik wichtig.

Summary

Remarkable advances in pediatric rheumatology have improved long term prognosis of juvenile idiopathic arthritis (JIA) during the last 15 years. The ILAR classification for JIA is increasingly accepted for chronic arthritis. Core sets of improvement have been developed, which enable decision whether or not the patient has improved during course. Concerning diagnosis, the identification of genetic defects in periodic fever syndromes like the Muckle-Wells-Syndrome, allow a clear differentiation to systemic JIA (sJIA). Methotrexate (MTX) remains “gold standard” as a disease modifying drug for JIA. An international multicenter study, however, showed that insufficient efficacy of the drug cannot be improved by increasing the dosage over 15 mg MTX/ m ²/week. For those cases Etanercept can be considered, which however is often ineffective in sJIA. Among the imaging procedures sonography holds an exceptional position due to its missing radial exposition and the possibility to frequently repeat the examination. Radiography is still important for follow-up of JIA and together with magnetic resonance imaging plays a dominant role for differential diagnosis.

Schlüsselwörter

Juvenile idiopathische Arthritis - Klassifikation - Diagnostik - Therapie

Keywords

Juvenile idiopathic arthritis - classification - diagnosis - treatment

Full Text

References

Literatur
1 Avcin T., Cimaz R., Falcini F. et al Prevalence and clinical significance of anticyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2002; 61: 608-11.
2 Berntson L., Fasth A., Andersson-Gare B. et al. Construct validity of ILAR and EULAR criteria in juvenile idiopathic arthritis: a population based incidence study from the Nordic countries. International League of Associations for Rheumatology. European League Against Rheumatism. J Rheumatol 2001; 28: 2737-43.
3 Bollow M., Biedermann T., Kannenberg J. et al Use of dynamic magnetic resonance imaging to detect sacroiliitis in HLA-B27 positive and negative children with juvenile arthritides. J Rheumatol 1998; 25: 556-64.
4 Brewer EJ., Bass J., Baum J. et al Current proposed revision of JRA criteria. Arthritis Rheum 1977; 20: 195-9.
5 Brewer EJ., Bass J., Cassidy JT. et al Criteria for the classification of juvenile rheumatoid arthritis. Bull Rheum Dis 1973; 23: 712-9.
6 Brown SL., Greene MH., Gershon SK. et al Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2004; 46: 3151-8.
7 Cassidy JT., Levinson JE., Bass JC. et al A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum 1986; 29: 274-81.
8 De Benedetti F., Martini A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis?. Arthritis Rheum 2005; 52: 687-93.
9 Foeldvari I., Ruperto N., Dressler F. et al The German version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001; 19: 71-75.
10 Gerloni V., Pontikaki I., Gattinara M. et al Efficacy of repeated intravenous infusions of an antitumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum 2005; 52: 548-53.
11 Giannini EH., Brewer EJ., Kuzmina N. et al Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med 1992; 326: 1043-9.
12 Giannini EH., Ruperto N., Ravelli A. et al Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
13 Häfner R. Bedeutung der bildgebenden Verfahren für Diagnose und Verlauf der juvenile Arthritis – Unterschiede zum Erwachsenen. Akt Rheumatol 2002; 27: 253-8.
14 Häfner R. Juvenile idiopathische Arthritis. Die neue Nomenklatur und Klassifikation der chronischen Arthritis im Kindesalter. Akt Rheumatol 2002; 27: 18-21.
15 Hawkins PN., Bybee A., Aganna E., McDermott MF. Response to anakinra in a de novo case of neonatalonset multisystem inflammatory disease. Arthritis Rheum 2004; 50: 2708-9.
16 Hawkins PN., Lachmann HJ., Aganna E., McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50: 607-12.
17 Hofer MF., Mouy R., Prieur AM. Juvenile idiopathic arthritides evaluated prospectively in a single center according to the Durban criteria. J Rheumatol 2001; 28: 1083-90.
18 Horneff G., Forster J., Seyberth HW., Michels H. Empfehlungen der Arbeitsgemeinschaft Kinderund Jugendrheumatologie zur Therapie mit Etanercept. Monatsschr Kinderheilk 2001; 149: 1066-9.
19 Horneff G., Schmeling H., Biedermann T. et al The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 1638-44.
20 Hull KM., Shoham N., Chae JJ. et al The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr Opin Rheumatol 2003; 15: 61-9.
21 Kastner DL. The hereditary periodic fevers. In Hochberg MC. et al. eds Rheumatology. Edinburgh: Mosby; 2003: 1717-34.
22 Keystone EC. Safety of biologic therapies – an update. J Rheumatol 2005; 32 (Suppl. 74) Suppl. 8-12.
23 Keystone EC., Schiff MH., Kremer JM. et al Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 353-63.
24 Krumrey-Langkammerer M., Häfner R. Evaluation of the ILAR criteria for juvenile idiopathic arthritis. J Rheumatol 2001; 28: 2544-7.
25 Lovell DJ., Giannini EH., Reiff A. et al Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003; 48: 218-9.
26 Lovell DJ., Giannini EH., Reiff A. et al Etanercept in children with polyarticular juvenile rheumatoid arthritis. The New England Journal of Medicine 2000; 342: 763-9.
27 Manners P., Lesslie J., Speldewinde D., Tunbridge D. Classification of juvenile idiopathic arthritis: should family history be included in the criteria?. J Rheumatol 2003; 30: 1857-63.
28 Michels H. Juvenile Arthritis (JCA, M08). In Zeidler H., Zacher J., Hiepe F. eds Interdisziplinäre klinische Rheumatologie. Berlin: Springer; 2001: 674-94.
29 Petty RE., Cassidy JT. Introduction to the study of rheumatic diseases in children. In Petty RE., Cassidy JT. eds Textbook of Pediatric Rheumatology. Philadelphia: W. B. Saunders Company; 2001: 2-8.
30 Petty RE., Southwood TR., Baum J. et al Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25: 1991-4.
31 Petty RE., Southwood TR., Manners P. et al International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2.
32 Quartier P., Taupin P., Bourdeaut F. et al Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003; 48: 1093-101.
33 Ravelli A., Felici E., Magni-Manzoni S. et al. Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum 2005; 52: 826-32.
34 Reddy AR., Backhouse OC. Does etanercept induce uveitis?. Br J Ophthalmol 2003; 87: 925.
35 Reiff A. Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis Rheum 2003; 48: 2079-80.
36 Reiff A., Takei S., Sadeghi S. et al Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001; 44: 1411-5.
37 Rosenbaum JT. Effect of etanercept on iritis in patients with ankylosing spondylitis. Arthritis Rheum 2004; 50: 3736-7.
38 Ruperto N., Murray KJ., Gerloni V. et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50: 2191-201.
39 Ruperto N., Ravelli A., Falcini F. et al Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Italian Pediatric Rheumatology Study Group. Ann Rheum Dis 1998; 57: 38-41.
40 Smith JA., Thompson DJ., Whitcup SM. et al A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005; 53: 18-23.
41 Smith JR., Levinson RD., Holland GN. et al Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001; 45: 252-7.
42 Symmons DP., Silman AJ. Antitumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum 2004; 50: 1703-6.
43 Thomson W., Barrett JH., Donn R. et al. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology (Oxford) 2002; 41: 1183-9.
44 Tiliakos AN., Tiliakos NA. Ocular inflammatory disease in patients with rheumatoid arthritis taking etanercept: Is discontinuation necessary?. J Rheumatol 2003; 30: 2727.
45 Truckenbrodt H., Häfner R. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum 1986; 29: 801-7.
46 Tsitsami E., Bozzola E., Magni-Manzoni S. et al. Positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. Arthritis Rheum 2003; 49: 488-93.
47 van Gestel AM., Prevoo ML., van 't Hof MA. et al Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34-40.
48 van Rossum M., van Soesbergen R., de Kort S. et al Anticyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol 2003; 30: 825-8.
49 Wallace CA., Ruperto N., Giannini EH. et al Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2290-4.
50 Wallace CA., Sherry DD. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J Rheumatol 1992; 19: 1604-7.
51 Wolfe F., Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740-51.
52 Wood P. Nomenclature and classification of arthritis in children. In Munthe E. ed. The Care of Rheumatic Children. Basle: EULAR Publishers; 1978: 47-50.
53 Yokota S., Miyamae T., Imagawa T. et al Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 818-25.